← Tra cứu cổ phiếu

iShareInvest Research

UPCOM · Quý 2/2026

DP2

Dược phẩm Trung ương 2

Analysis of business results & financial statements · Quý 2/2026

▼▼ Declining sharply

Trailing net profit reached 16.5bn, fell 10.0bn compared with the same period last year. Key positives came from better other profit. Offsetting pressure came mainly from higher finance costs and lower gross profit. Detailed impact is shown below:

See what is changing ↓
P/E
-5.95x
P/B
1.61x
EPS
-823
BVPS
3,051
ROE
-23.7%
ROA
-5.0%
Market price
4,900
03 Jul 2026

What Is Changing

On a TTM 2026Q2 basis, DP2 posted a very sharp profit drop versus the same period, showing that pressure has clearly fed through to the bottom line. More notably, profit is significantly supported by non-core sources and operating cash flow is not yet positive — the earnings quality picture needs close monitoring.

Profit bridge

Vs last year · TTM

  1. Other profit
  2. Finance costs
  3. Gross profit
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 2/2026

MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue39.529.445.049.962.741.551.843.8
LNST-2.3-6.9-4.9-2.40.5-3.52.4-5.8
Net margin-5.73%-23.46%-10.92%-4.81%0.74%-8.32%4.55%-13.28%

Revenue

39bn

Net income

-2bn

Net margin

-5.73%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins are under pressure while earnings still rely significantly on non-core sources.

Revenue Growth

▼▼

Is growth real and durable?

Trailing-12-month revenue declined 18.1% year on year — but the quarterly pace is slowing (+14% → −37%).

1 of the last 4 quarters grew year on year.

Revenue TTM
164bn
−18.1%
Latest quarter YoY
−37%
slowing

What is driving the margin?

▼▼

Net margin fell to −10.06%, losing 6.8pp. The main pressure comes from SG&A / Revenue rose 1.6pp and Gross margin fell 0.9pp (in addition, Other profit / Revenue rose 0.6pp added support while Net financial result / Revenue fell 4.9pp remained a drag).

Margin is under pressure from multiple sides — temporary and structural components need to be separated to properly assess the risk.

Net Margin
−10.06%
−6.8pp
Gross Margin
8.67%
−0.9pp
SG&A / Revenue
11.50%
+1.6pp
Non-core / Revenue
−7.23%
−4.3pp

TTM YoY · 2025Q2 -> 2026Q2

Financial result share remains high

Even though contribution decreased by 4.3pp, financial result still accounts for 76.8% of PBT — earnings durability should be monitored in coming periods.

Cash Flow

●

Is profit converting into cash?

Leverage needs watching — cash flow shows the ability to service debt from operations. Operating cash flow reached 21.7bn against investing cash flow of -0.6bn (annual cash-flow figures for 2025).

Post-investment cash flow was positive +21.0bn. Financing cash flow was negative +4.7bn.

CFO / net income was −1,16 lần.

Track how much investment can be funded internally from operating cash flow.

Cash capex or FCF data is incomplete, so the cash-conversion view is only partial.

Earnings Quality

▼

How much income is non-core?

Non-core income reaches 76.8% of pre-tax profit — core earnings are thinner than the headline.

Within that, net financial result at +74.3%, other profit at +2.5% of PBT.

Non-core / PBT
76.8%
high
Net financial / PBT
74.3%
Other profit / PBT
2.5%
02

Is capital being used efficiently?

Capital efficiency should be read in industry context — ROIC may fluctuate with business specifics.

Is capital being deployed efficiently?

●

Track how much operating profit the business generates on invested capital.

Industry characteristics make ROIC cyclical — this is a reference signal and should be read with the business context.

Working Capital Efficiency

▼▼

Cash conversion cycle lengthened by 33.9 days versus the same period last year. The main moves came from DIO rose 49.1 days, DSO fell 1.9 days, and DPO rose 13.2 days.

Working capital cycle lengthened mainly due to slower inventory turnover — more capital is being tied up in inventory.

Cash conversion cycle remains stretched

CCC stands at 132.6 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Inventory turnover is slowing

DIO increased by +49.1 days, suggesting more capital is being tied up in inventories.

DuPont

What drives ROE?

Net margin -10.1% -6.8pp
Asset turnover 0.50x +0.06x
Financial leverage 4.75x -0.82x
ROE -23.7% +15.8pp

ROE fell from −7.9% to −23.7% — dragged by net margin and leverage.

03

Is financial risk significant?

Check leverage, liquidity, and cash-flow conversion.

Leverage & Liquidity

▼▼

Leverage warrants monitoring, with net debt / equity at 0.25x and interest coverage only at −1.37x.

At present, short-term debt accounts for 100.0% of total debt, cash equals 23.0% of debt, and total debt stands at 4.8bn.

Net Debt / Equity
0.25x
−0.94x
Interest Coverage
−1.37x
−0.25x
Cash / Debt
23.0%
+13.5pp
Short-term Debt / Total Debt
100.0%
0.0pp

TTM YoY · 2025Q2 -> 2026Q2

Interest coverage is thin

Interest coverage is −1.37x, leaving limited room to absorb financing costs.

Short-term refinancing pressure is meaningful

Short-term debt accounts for 100.0% of total debt, raising near-term refinancing needs.

Balance Sheet

▼▼

Leverage is very high, with clear pressure on the capital structure — liabilities at 4.85x equity, net debt at 0.25x equity.

Inventory ended the period at 41.6bn, roughly 10.1% of total assets.

Over the last 12 months, working capital released 0.0bn of cash.

Research synthesis

What this reporting period is showing

The business is showing a few weaker signals, but the current magnitude is not yet clear enough to conclude that this is a broader weakening phase. Even so, earnings quality still needs closer monitoring because net financial result remains elevated. The main risk still sits in core profitability, with net margin down 6.8 pp.

  • Watchpoint: the earnings mix still needs monitoring, with net financial result still accounting for 74.3% of PBT and CFO / net income currently at −1.16x.
  • Key risk: profitability remains under pressure, with trailing-12M net margin at -10.06% after a 6.8pp decline versus the same period last year.

Questions for the next period

  1. Whether revenue stabilizes after a −18,1% YoY decline or keeps falling.

  2. Whether margins hold around the current -10.06% level or narrow again.

  3. Whether operating cash flow holds its 21.7bn (cumulative for 2025) level in upcoming periods or weakens.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio